한국유니온제약

080720KOSDAQSector: Pharma & Biotech

₩2,725 0.00%Market cap ₩21.6BAs of Jul 21, 2026 close · updated once daily

Grade F6.8 ptsTop 100% of 2,523 stocks

Financial strength

9.3

Growth momentum

11.5

Price attractiveness

0.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

9.3

How much debt does it carry relative to equity?

Debt-to-equity ratio

Negative equity (not computable)

✗ Below median · Top 99.4% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

33.7%

✗ Below median · Top 97.4% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-47.4%

✗ Below median · Top 66.5% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

Negative equity (not computable)

✗ Below median · Top 99.4% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

11.5

How much did revenue grow in a year?

Revenue growth (YoY)

-29.1%

✗ Below median · Top 92% in sector

Sector median 6.4%

Has it grown steadily over three years?

Revenue 3-year CAGR

-16.0%

✗ Below median · Top 88.2% in sector

Sector median 4.9%

Did core profits grow in a year?

Operating income change (YoY)

-28.1%

✗ Below median · Top 75.7% in sector

Sector median 3.6%

Are core profits higher than three years ago?

Operating income change (3Y)

-1455.3%

✗ Below median · Top 98.1% in sector

Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

0.6

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 99% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

Negative equity (not computable)

✗ Below median · Top 99.8% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15